Seppic, a subsidiary of Air Liquide Healthcare, and Botalys, a Belgian start-up specialized in the cultivation of rare and medicinal plants, have signed a research partnership for the co-development of new ingredients for the cosmetics and health markets. This partnership is completed with a series of distribution contracts in various markets and geographies, for Botalys’ Ginseng-based products.
Botalys produces “ultra-pure and efficient” botanical ingredients from a technology of vertical farming based on an innovative process. The company supplies ingredients and medicinal plants to a multitude of clients and partners in the cosmetics, dietary supplements and pharmaceutical industries.
“We are very pleased with this new partnership with Botalys. This agreement is fully in line with our corporate strategy to develop natural ingredients based on innovative technologies and to distribute exclusive ingredients for the cosmetics and dietary supplements markets, while strengthening our position in the development of new supply chains,” said Hannes Moeller, CEO of Seppic.
“Our patented and innovative precision farming technology addresses the need for purity, efficacy, and security of supply of many rare medicinal plants. This scientific and commercial partnership outlines the huge potential of this technology for the nutraceutical and cosmetic industry,” added Pierre-Antoine Mariage, CEO of Botalys.
This partnership follows the announcement on September 29 by ALIAD, the Air Liquide Group’s Venture Capital Fund, of its investment in Botalys, in line with its strategy of taking positions in impact start-ups.